@article{ee480bfed6d3448a887bae0d2099cd58,
title = "Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia",
keywords = "chronic myeloid leukaemia, immunology, minimal residual disease, treatment-free remission",
author = "Ross, \{David M.\} and Pagani, \{Ilaria S.\} and Irani, \{Yazad D.\} and Jade Clarson and Tamara Leclercq and Phuong Dang and Jennifer McLean and Saunders, \{Verity A.\} and Lisa Carne and John Reynolds and Ritchie, \{David S.\} and White, \{Deborah L.\} and Susan Branford and Hughes, \{Timothy P.\} and Yong, \{Agnes S.M.\}",
note = "Funding Information: This study was sponsored by the South Australian Health and Medical Research Institute (SAHMRI), and funded by research grants from Celgene and the National Health \& Medical Research Council of Australia (APP1138935) to SAHMRI. The authors are grateful to the patients who participated in this study, and to Liddy Griffith and Juanita Ottaway of SAHMRI Clinical Research.",
year = "2019",
month = aug,
doi = "10.1111/bjh.15894",
language = "English",
volume = "186",
pages = "e56--e60",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley and Sons Inc.",
number = "3",
}